CAR-T细胞免疫治疗实体瘤的研究进展

Advances of research on CAR-T cell immunotherapy for solid tumors

近年来过继性细胞免疫疗法因效果显著而得到广泛认可,尤其是CD19特异嵌合抗原受体(CAR)的自体T细胞治疗恶性血液瘤取得成功。本文总结实体肿瘤存在肿瘤免疫微环境、靶点不均一以及免疫抑制性受体等原因导致CAR-T无法有效治疗,提出改进CAR-T细胞以提高T细胞浸润、共表达细胞因子与酶以及修饰相关受体等方式提高CAR-T抗实体肿瘤活性,为后续CAR-T细胞治疗实体肿瘤研究奠定理论基础。

Adoptive cellular immunotherapy has been widely recognized in recent years due to its remarkable results,especially the success of CD19-specific chimeric antigen receptor(CAR)autologous T cell therapy for malignant hematoma.Previous studies have found the existence of tumor immune microenvironment,heterogeneous targets,and immunosuppressive receptors in solid tumors,which has led to the shortcomings of CAR-T treatment of solid tumors.This article proposes the methods to improve CAR-T cells to increase T cell infiltration,co-expression of cytokines and enzymes and modification of related receptors in order to enhance the anti-solid tumor activity of CAR-T,laying a theoretical foundation for the follow-up CAR-T cell treatment of solid tumors.